VYNE Therapeutics is a biopharmaceutical company that develops therapies for the treatment of immuno-inflammatory conditions. Co.'s primary program is VYN201, an administered pan-bromodomain and extra-terminal (BET) inhibitor to address diseases involving multiple inflammatory cell signaling pathways while providing low systemic exposure. Co.'s second program is VYN202, a BD2-selective oral small molecule BET inhibitor. VYN202 is in preclinical development for the treatment of immuno-inflammatory indications. FMX114 is Co.'s proprietary investigational combination gel formulation of tofacitinib and fingolimod that addresses both the source and cause of inflammation in atopic dermatitis. The VYNE average annual return since 2018 is shown above.
The Average Annual Return on the VYNE average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether VYNE average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the VYNE average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|